title: Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate.
abstract: Drug hepatotoxicity is partially determined by genetic factors involved in drug metabolism, which may involve the debrisoquine oxidation polymorphism mediated by cytochrome (CYP) 2D6. The purpose of this study was to assess the relationship between drug hepatotoxicity and another genetic polymorphism of drug oxidation, namely that of S-mephenytoin metabolism mediated by CYP2CMP. Mephenytoin hydroxylation capacity was assessed by a hydroxylation index in 24 patients with drug-induced hepatitis and in 23 healthy controls. Hydroxylation index was calculated as the ratio of S-mephenytoin dose to the (0-10 h) urinary excretion of 4-hydroxymephenytoin after oral administration of 100 mg racemic mephenytoin. The test was performed following the patient's recovery. In three patients, hepatitis was related to Atrium, a drug containing phenobarbital, febarbamate and difebarbamate. The mean hydroxylation index (+/- SD) value in patients with Atrium hepatitis (12.4 +/- 8.3) was markedly higher than that found in healthy controls (1.8 +/- 0.4) or in patients with other drug-induced hepatitis (2.5 +/- 3.3). Mean hydroxylation index values were similar in the two latter groups. Considered individually, oxidation capacity was low (hydroxylation index > 9) in two of the three patients with Atrium hepatitis and intermediate (hydroxylation index between 4 and 9) in the third patient. In contrast, all 23 healthy subjects exhibited a high oxidation capacity (hydroxylation index < 4). In the 21 patients with other drug-induced hepatitis, oxidation capacity was high in 19 subjects, intermediate in one subject with chlorpromazine hepatitis, and low in one subject with dapsone hepatitis.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Unité de Recherches de Physiopathologie Hépatique (INSERM U 24), Hôpital Beaujon, Clichy, France.
authors.forename: Y
authors.initials: Y
authors.lastname: Horsmans
authors.forename: D
authors.initials: D
authors.lastname: Lannes
authors.forename: D
authors.initials: D
authors.lastname: Pessayre
authors.forename: D
authors.initials: D
authors.lastname: Larrey
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001463:Barbiturates / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000378:metabolism; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006900:Hydroxylation; D008099:Liver / Q000187:drug effects*; D008297:Male; D008617:Mephenytoin / Q000378:metabolism*; D008875:Middle Aged; D010084:Oxidation-Reduction; D010634:Phenobarbital / Q000009:adverse effects*; D011446:Prospective Studies
chemical_list: D001463:Barbiturates; D004338:Drug Combinations; C006648:difebarbamate, febarbamate, phenobarbital drug combination; D008617:Mephenytoin; D010634:Phenobarbital